Literature DB >> 23771936

Psychiatric side effects of mefloquine: applications to forensic psychiatry.

Elspeth Cameron Ritchie1, Jerald Block, Remington Lee Nevin.   

Abstract

Mefloquine (previously marketed in the United States as Lariam®) is an antimalarial medication with potent psychotropic potential. Severe psychiatric side effects due to mefloquine intoxication are well documented, including anxiety, panic attacks, paranoia, persecutory delusions, dissociative psychosis, and anterograde amnesia. Exposure to the drug has been associated with acts of violence and suicide. In this article, we discuss the history of mefloquine use and describe plausible mechanisms of its psychotropic action. Mefloquine intoxication has not yet been successfully advanced in legal proceedings as a defense or as a mitigating factor, but it appears likely that it eventually will be. Considerations for the application of claims of mefloquine intoxication in forensic settings are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771936

Source DB:  PubMed          Journal:  J Am Acad Psychiatry Law        ISSN: 1093-6793


  16 in total

Review 1.  Malaria medicines: a glass half full?

Authors:  Timothy N C Wells; Rob Hooft van Huijsduijnen; Wesley C Van Voorhis
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

Review 2.  Cardiac to cancer: connecting connexins to clinical opportunity.

Authors:  Christina L Grek; J Matthew Rhett; Gautam S Ghatnekar
Journal:  FEBS Lett       Date:  2014-03-04       Impact factor: 4.124

Review 3.  Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Authors:  Remington L Nevin; Ashley M Croft
Journal:  Malar J       Date:  2016-06-22       Impact factor: 2.979

4.  Connexin-Based Therapeutics and Tissue Engineering Approaches to the Amelioration of Chronic Pancreatitis and Type I Diabetes: Construction and Characterization of a Novel Prevascularized Bioartificial Pancreas.

Authors:  J Matthew Rhett; Hongjun Wang; Heather Bainbridge; Lili Song; Michael J Yost
Journal:  J Diabetes Res       Date:  2015-12-14       Impact factor: 4.011

5.  Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy.

Authors:  Nicole M Maxwell; Remington L Nevin; Stephen Stahl; Jerald Block; Sarah Shugarts; Alan H B Wu; Stephen Dominy; Miguel Alonso Solano-Blanco; Sharon Kappelman-Culver; Christopher Lee-Messer; Jose Maldonado; Andrew J Maxwell
Journal:  Clin Case Rep       Date:  2015-04-09

6.  Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: a case report.

Authors:  Manish Jain; Remington L Nevin; Iajaz Ahmed
Journal:  J Med Case Rep       Date:  2016-10-31

Review 7.  Rational Risk-Benefit Decision-Making in the Setting of Military Mefloquine Policy.

Authors:  Remington L Nevin
Journal:  J Parasitol Res       Date:  2015-10-22

Review 8.  Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force.

Authors:  Stuart McCarthy
Journal:  J Parasitol Res       Date:  2015-12-17

Review 9.  Complex Membrane Channel Blockade: A Unifying Hypothesis for the Prodromal and Acute Neuropsychiatric Sequelae Resulting from Exposure to the Antimalarial Drug Mefloquine.

Authors:  Jane C Quinn
Journal:  J Parasitol Res       Date:  2015-10-20

10.  Potentiation of Amitriptyline Anti-Hyperalgesic-Like Action By Astroglial Connexin 43 Inhibition in Neuropathic Rats.

Authors:  Tiffany Jeanson; Adeline Duchêne; Damien Richard; Sylvie Bourgoin; Christèle Picoli; Pascal Ezan; Franck Mouthon; Christian Giaume; Michel Hamon; Mathieu Charvériat
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.